Spotlight On Asian Undervalued Small Caps With Insider Buying July 2025

As global markets navigate the complexities of new U.S. tariffs and mixed economic data, small-cap stocks in Asia present intriguing opportunities amid broader market uncertainties. In this environment, identifying promising small-cap stocks often involves looking for those with strong fundamentals and insider confidence, which can be particularly appealing when broader market sentiment is cautious.

Top 10 Undervalued Small Caps With Insider Buying In Asia

Click here to see the full list of 43 stocks from our Undervalued Asian Small Caps With Insider Buying screener.

Here's a peek at a few of the choices from the screener.

Iluka Resources (ASX:ILU)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Iluka Resources is a leading Australian company specializing in the exploration, project development, operations, and marketing of mineral sands products, with a market cap of A$5.23 billion.

Operations: Iluka Resources' revenue primarily stems from the Mineral Sands segment, amounting to A$1.17 billion. The company's gross profit margin has shown fluctuations, reaching 65.00% in Q3 2022 before declining to 56.64% by the end of 2024. Operating expenses have consistently impacted profitability, with significant allocations towards depreciation and amortization as well as sales and marketing efforts over recent periods.

PE: 8.8x

Iluka Resources, a small-cap player in the Asian market, is catching attention with their high-quality earnings and promising growth trajectory. Revenue is forecasted to grow by 13.93% annually, highlighting potential for expansion. Recently, insider confidence has been bolstered by share purchases over the past year. The appointment of James Mactier as Chair brings seasoned leadership from his tenure at Macquarie and Regis Resources. Despite relying solely on external borrowing for funding, Iluka's strategic direction suggests promising prospects ahead.

• Delve into the full analysis valuation report here for a deeper understanding of Iluka Resources.

• Examine Iluka Resources' past performance report to understand how it has performed in the past.

China XLX Fertiliser (SEHK:1866)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: China XLX Fertiliser is a company engaged in the production and sale of chemical fertilizers and related products, with a market capitalization of approximately CN¥10.46 billion.

Operations: The primary revenue streams include urea, methanol, and compound fertiliser. The gross profit margin has shown fluctuations, reaching 24.49% in September 2021 and declining to 16.91% by December 2024. Operating expenses have varied over time, with notable components being general and administrative expenses alongside sales and marketing costs.

PE: 4.9x

China XLX Fertiliser, a company with a smaller market cap, is drawing attention for its potential growth prospects. Despite relying solely on external borrowing for funding, which carries higher risk, the company forecasts earnings growth of 19.89% annually. Recent insider confidence was demonstrated through share purchases in early 2025. Governance changes include appointing Mr. Man Yun Wah and Ms. Cheok Hui Yee as joint company secretaries in June 2025 to strengthen corporate governance practices and ensure continuity in management oversight.

• Navigate through the intricacies of China XLX Fertiliser with our comprehensive valuation report here.

• Gain insights into China XLX Fertiliser's past trends and performance with our Past report.

Abbisko Cayman (SEHK:2256)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Abbisko Cayman is a biopharmaceutical company focused on the development of innovative medicines, with a market capitalization of CN¥1.54 billion.

Operations: The company primarily generates revenue from the development of innovative medicines, with a recent figure reaching CN¥503.99 million. Operating expenses are significant, driven mainly by R&D costs and general administrative expenses. The net income margin has shown improvement over time, moving from negative to positive in recent periods. Gross profit margin consistently stands at 1.00%.

PE: 195.6x

Abbisko Cayman, a company with promising growth potential in Asia's small-cap landscape, is navigating challenges with an innovative edge. The company recently advanced its pipeline with the first patient enrollment for ABSK061 in treating Achondroplasia and initiated dosing for irpagratinib targeting Hepatocellular Carcinoma. Despite earnings forecasted to decline by 61.4% annually over three years, insider confidence is evident as founder Yao-Chang Xu purchased 45,000 shares worth approximately HK$291,600 in June 2025. However, reliance on external borrowing presents funding risks.

• Take a closer look at Abbisko Cayman's potential here in our valuation report.

• Assess Abbisko Cayman's past performance with our detailed historical performance reports.

Next Steps

• Unlock more gems! Our Undervalued Asian Small Caps With Insider Buying screener has unearthed 40 more companies for you to explore.Click here to unveil our expertly curated list of 43 Undervalued Asian Small Caps With Insider Buying.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com